This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Wm Smith Research Initiates Coverage Of Nymox

HASBROUCK HEIGHTS, N.J., Sept. 13, 2012 (GLOBE NEWSWIRE) -- Wm Smith Special Opportunities Research Company has initiated coverage of Nymox Pharmaceutical Corporation (Nasdaq:NYMX) with a 12 month target price of $16.00. The report was written by Sameer Harish, an equity research analyst.  According to the report, Nymox "is engaged in multiple clinical programs with NX-1207, a novel candidate to treat the symptoms of benign prostatic hyperplasia (BPH) and prostate cancer. We strongly believe that NX-1207 represents a significant advancement in the treatment of Lower Urinary Tract Symptoms (LUTS) and, over time, may become standard of care for BPH."  The report estimates that "the BPH market may represent a $1 billion-plus annual opportunity for NX-1207 in the United States."

About Nymox: NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials for BPH and in Phase 2 trials for low risk localized prostate cancer. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials for BPH where a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. NX-1207 is injected directly into the prostate by a urologist in an office setting and involves little or no pain or discomfort.  For more information about the NX-1207 clinical trials please go to or contact Nymox at .

BPH or enlarged prostate is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80 and is associated with growth in prostate size as men age. BPH causes progressive difficulties with urination, such as nocturia, urge to void frequently, acute urinary retention and other problems. The condition can seriously impact the health and quality of life of middle aged and older men. An estimated 100 million men worldwide being estimated to suffer from BPH symptoms. More information about Nymox is available at , email: , or 800-936-9669.  Nymox made no payments to Wm Smith for the research report.

About Wm Smith Special Opportunities Research Company: Wm Smith Special Opportunities Research Company is an affiliate of Wm Smith & Co. Wm Smith & Co. is an independent research company providing objective, fundamental equity research on "special situations" (primarily under-followed and under-valued) companies to a select group of institutional clients from both the traditional and alternative investment arena. Wm Smith has no investment bank, consulting, or other revenue-generating relationship with Nymox and the analyst did not receive any compensation from the company.  For more information visit: or call 800-757-1175.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

CONTACT: Roy Wolvin
         Nymox Pharmaceutical Corporation

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs